Cardiff Oncology Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $120.000K Beat $112.500K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.20) by 15.42 percent. This is a 32 percent increase over losses of $(0.25) per share from the
